The arrival of amivantamab offers a significant development for patients battling cancers exhibiting c-MET overexpression. This innovative antibody, a selective blocker of both MET kinase and human epidermal growth https://zaynidym657805.blog5.net/92167436/amivantamab-a-new-treatment-for-c-met-associated-growths